Thermo Fisher Scientific Inc.
TMOHealthcareNASDAQDiagnostics & Research · Last scanned Oct 26, 2026
Scan Results
Daily timeframeThermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. At a $249.14B market cap, Thermo Fisher Scientific Inc. ranks as a mega-cap company within healthcare. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Market Cap
$249.14B
Beta
0.88
P/E (TTM)
35.54
P/E (Fwd)
24.29
EPS (TTM)
$18.96
EPS (Fwd)
$27.74
ROE
13.4%
ROA
5.2%
Cash
$6.06B
Total Debt
$41.37B
Free CF
$6.45B
52W Change
19.5%
Annual Financials
Cash vs Debt
Where TMO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TMO finished 24.80% above its 150-day moving average ($544.37) and 24.19% above its 200-day moving average ($547.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TMO overbought or oversold?
At the October 20, 2026 close, TMO's RSI(14) was 49.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $6.06B in cash, though total debt stands at $41.37B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $6.45B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 13.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $39.21B to $44.56B.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TMO.